Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood gas device put to the test – but trial halted early

NCT ID NCT02801162

Diagnosis Sponsor: Universitair Ziekenhuis Brussel Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared a new device, the Proxima 3®, to standard hospital equipment for measuring blood gases like oxygen and carbon dioxide. Researchers wanted to see if the new device was accurate and fast in patients whose condition was changing quickly. The trial was stopped early after enrolling only 20 adults with arterial lines, so the findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Proxima 3® arterial blood gas analysis system
What this could lead to
If successful, this could provide a faster, reliable way to measure blood gases in rapidly changing clinical situations.
What could go wrong
The trial was terminated early with only 20 participants, so results are limited and may not be conclusive.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Sep 2016

Finished

Apr 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female patients ≥18 years old * Patients who have (or will have) an arterial line, which was (will be) inserted for clinical - need, will be considered for inclusion in this study * Patients who give informed consent (or their personal/nominated consultee) to participate in the study * Patients who are likely to have an arterial line for at least 6 hours. Exclusion Criteria: * Patients contraindicated for an arterial line * Refusal of consent by a patient * Not for use with patients with uncorrected hyperphosphataemia, hypocalcaemia or hypercalcaemia. * The patient is considered to be unsuitable for the study by the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anaemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia Hypercapnia Hypoxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anaemia Hypercapnia Hypoxia

Contacts and locations

Locations

  • Universitair Ziekenhuis Brussel

    Jette, Vlaams-Brabant, 1090, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.